FDA approves Takeda's self-administered Entyvio for Crohn's

Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) version of Entyvio, its treatment for adults with moderate to severe Crohn’s disease (CD).

Related Keywords

Timothy Ritter , Gi Alliance Research , School Of Medicine , Brandon Monk , Business Unit , Entyvio Pen , Markets Amp Regulations , Makeda , Crohn 039s Disease , Fda , Clinical Trial ,